in an Initial Study is Planned to Commence Q2/2013; Multi-Site Initiation Process is Underway; Newly Issued Patent Expires no Earlier Than 2029

Additional Planned and Required Studies, Which Include a Second Phase III Crohn’s Disease Trial in Europe and Other , Are Under Preparation as Part of ’s Development and

RedHill Ltd. RDHL 0.00% (tase:RDHL) (the “Company” or “RedHill ”), an emerging Israeli primarily on the development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, reported today the issuance of a new U.S. patent and that a multi-site initiation process is underway in the U.S., and for a first multi-center, randomized, double-blind, placebo-controlled, initial Phase III study (the “MAP US Study”) to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with moderately to severely active Crohn’s disease. The MAP US Study will be conducted under an Investigational New Drug (IND) application amended in August 2012 and recruitment is planned to commence in the second quarter of 2013.

RedHill Biopharma Announces Issuance of New US Patent and Provides
MarketWatch (press release)
In addition to the MAP US Study which is designed to provide insights into safety and efficacy of RHB-104 and initial assessment of the role of MAP in Crohn’s disease, the Company is planning and preparing for a Phase III clinical trial in Europe with and more »

About Rob Hill

In 1994, Rob was a fit, healthy 23-year-old, an amateur runner and athlete. Until that time, he had never really been sick. He didn’t even have a regular doctor. When the illness started, it progressed rapidly. Daily diarrhea. Sustained stomach cramps. The diagnosis was Crohn’s disease, an inflammatory condition of the digestive tract. It got worse, and his weight plummeted from 185 to 105 pounds. After a year and a half, it became clear that his large intestine, his colon, needed to be removed. Rob decided he had to do something about it. The Seven Summits campaign, which we call “No Guts Know Glory” grew from Rob’s love of sport, adventure and the outdoors. By taking it to the extreme, and on a global basis, Rob hopes to show people everywhere that having these diseases or having an ostomy, like Rob does, shouldn’t stop you from leading a full life. You may not be able to climb mountains, but there are so many other things you can do. To further this goal, Rob started the Intestinal Disease Education and Awareness Society (IDEAS), from his home base in Vancouver, British Columbia.

Leave a Reply